The share price of the cellular oncology drug developer, which counts Novartis, Johnson & Johnson and PureTech Health as investors, has doubled since it floated.
Vor Biopharma, a US-based cancer therapy developer backed by pharmaceutical firms Novartis, Johnson & Johnson and PureTech Health, has gone public in a $177m initial public offering. The company issued 9.83 million shares – increased from 8.8 million – on the Nasdaq Global Select Market priced at $18.00 each, at the top of the IPO’s…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
